In particular, mTORC1 activity is markedly elevated in SLE patients' T cells, which stimulates the production of IL-4 and IL-17 (224), while inhibiting Foxp3 expression, which reduces the immune-suppressive capacity of Treg cells (225). Here, FOXP3 is linked to systemic lupus erythematosus.